Kura Oncology (KURA) · ziftomenib + gilteritinib
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2026
data from the KOMET-008 cohort evaluating ziftomenib in combination with gilteritinib in patients with relapsed or refractory NPM1-mutated AML in 2026
· filed · SEC filing
After
Stated timing: second half of 2026
anticipate presenting preliminary data in the second half of 2026
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/KURA-ziftomenib-gilteritinib-2026-08-12, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/KURA-ziftomenib-gilteritinib-2026-08-12
Kura Oncology (KURA) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.